BrightSpring Health Services, Inc. (BTSG)
| Market Cap | 11.91B +226.4% |
| Revenue (ttm) | 13.65B +28.0% |
| Net Income | 309.89M +441.5% |
| EPS | 1.40 +386.0% |
| Shares Out | 205.65M |
| PE Ratio | 75.40 |
| Forward PE | 32.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,833,365 |
| Open | 57.62 |
| Previous Close | 58.40 |
| Day's Range | 57.21 - 58.30 |
| 52-Week Range | 19.01 - 58.67 |
| Beta | 1.72 |
| Analysts | Strong Buy |
| Price Target | 58.00 (+0.17%) |
| Earnings Date | May 1, 2026 |
About BTSG
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for BTSG stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 0.17% from the latest price.
News
BrightSpring Health price target raised to $66 from $63 at BofA
BofA analyst Joanna Gajuk raised the firm’s price target on BrightSpring Health (BTSG) to $66 from $63 and keeps a Buy rating on the shares. The tone of CFO Jennifer…
BrightSpring Health price target raised to $62 from $48 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $62 from $48 and keeps an Overweight rating on the shares.
BrightSpring Health price target raised to $61 from $52 at Mizuho
Mizuho analyst Ann Hynes raised the firm’s price target on BrightSpring Health (BTSG) to $61 from $52 and keeps an Outperform rating on the shares.
BrightSpring Health price target raised to $60 from $50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $50 and keeps a Buy rating on the shares.
BrightSpring Health price target raised to $60 from $52 at BMO Capital
BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an Outperform rating on the shares. The magnitude of the company’s Q1 earnings…
BrightSpring Health price target raised to $65 from $60 at TD Cowen
TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $65 from $60 and keeps a Buy rating on the shares. The firm updated its model following Q1…
BrightSpring Health price target raised to $64 from $53 at Stephens
Stephens raised the firm’s price target on BrightSpring Health (BTSG) to $64 from $53 and keeps an Overweight rating on the shares. BrightSpring’s 7% revenue and 12% EBITDA beat was…
BrightSpring Health price target raised to $65 from $55 at BTIG
BTIG raised the firm’s price target on BrightSpring Health (BTSG) to $65 from $55 and keeps a Buy rating on the shares after its Q1 earnings beat. While some investors…
BrightSpring Health price target raised to $61 from $50 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on BrightSpring Health (BTSG) to $61 from $50 and keeps an Overweight rating on the shares following very strong Q1…
BrightSpring Health price target raised to $60 from $55 at KeyBanc
KeyBanc raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $55 and keeps an Overweight rating on the shares. The firm says results were once again impressive,…
BrightSpring Health price target raised to $60 from $52 at BMO Capital
BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an Outperform rating on the shares.
BrightSpring Health Services Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth and 45% adjusted EBITDA growth, driven by strong specialty and infusion performance, operational efficiencies, and successful integration of acquisitions. Guidance for 2026 was raised, with continued focus on margin expansion and disciplined capital allocation.
BrightSpring Health Services, Inc. Reports First Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
LOUISVILLE, Ky., May 01, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services fo...
BrightSpring Health Services, Inc. to Announce First Quarter 2026 Financial Results on May 1, 2026
LOUISVILLE, Ky., April 07, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its first quarter 2026 ...
BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita
LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and hea...
BrightSpring Health price target raised to $55 from $53 at UBS
UBS raised the firm’s price target on BrightSpring Health (BTSG) to $55 from $53 and keeps a Buy rating on the shares.
BrightSpring Health price target raised to $60 from $49 at TD Cowen
TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $49 and keeps a Buy rating on the shares. The firm come away positive from investor…
BrightSpring Health price target raised to $55 from $53 at UBS
UBS analyst AJ Rice raised the firm’s price target on BrightSpring Health (BTSG) to $55 from $53 and keeps a Buy rating on the shares. At the investor day event…
BrightSpring Health price target raised to $52 from $50 at Mizuho
Mizuho raised the firm’s price target on BrightSpring Health (BTSG) to $52 from $50 and keeps an Outperform rating on the shares. The company’s investor day brought an “attractive” mid-double-digit…
BrightSpring Health Services Transcript: Investor Day 2026
Revised summary: The company’s strategy focuses on integrated home and community health, using scale, technology, and operational excellence for double-digit growth in pharmacy and provider segments. Guidance projects 15–20% organic EBITDA CAGR through 2028, backed by strong cash flow, disciplined M&A, AI investment, and regulatory engagement.
BrightSpring Health Services Transcript: Leerink Global Healthcare Conference 2026
Lean culture, centralized procurement, and AI initiatives are driving operational efficiency and margin improvement. Specialty pharmacy and infusion segments are growing through new therapies, LDD wins, and selective M&A, while provider businesses like Hospice and Home Health show strong performance and integration. Financial flexibility is increasing as leverage declines.
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services ...
BrightSpring Announces Secondary Offering of Common Stock and Concurrent Share Repurchase
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services ...
BrightSpring Health Services Transcript: TD Cowen 46th Annual Health Care Conference
Broad-based growth is expected across pharmacy and provider services, with strong EBITDA guidance and margin expansion driven by operational efficiencies, generics, and LDD launches. IRA headwinds are being mitigated, and integration of new assets plus a robust M&A pipeline support future growth.
BrightSpring Health Services Earnings Call Transcript: Q4 2025
Delivered 28% revenue and 34% adjusted EBITDA growth in 2025, exceeding guidance, with strong performance across segments and successful strategic acquisitions. 2026 guidance projects 12–16% revenue and 23–28% adjusted EBITDA growth, supported by operational efficiencies and integration of new assets.